MX2019004602A - Agentes anti-proliferativos para tratar pah. - Google Patents

Agentes anti-proliferativos para tratar pah.

Info

Publication number
MX2019004602A
MX2019004602A MX2019004602A MX2019004602A MX2019004602A MX 2019004602 A MX2019004602 A MX 2019004602A MX 2019004602 A MX2019004602 A MX 2019004602A MX 2019004602 A MX2019004602 A MX 2019004602A MX 2019004602 A MX2019004602 A MX 2019004602A
Authority
MX
Mexico
Prior art keywords
proliferative agents
treating pah
pulmonary
hypertension
pah
Prior art date
Application number
MX2019004602A
Other languages
English (en)
Inventor
Martin Evans Steven
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2019004602A publication Critical patent/MX2019004602A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se puede tratar hipertension pulmonar y enfermedades relacionadas, como hipertension arterial pulmonar, al administrar una dosis efectiva de un inhibidor de CDK, incluyendo palbociclib, 6-acetil-8-ciclopentil-5-metil-2-{[5-(piperazin-1-il) piridin-2il]amino}pirido[2,3-d]pirimidin-7(8H)-ona, o sal farmacéuticamente aceptable del mismo.
MX2019004602A 2016-10-20 2017-10-09 Agentes anti-proliferativos para tratar pah. MX2019004602A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410566P 2016-10-20 2016-10-20
US201762548629P 2017-08-22 2017-08-22
PCT/IB2017/056226 WO2018073687A1 (en) 2016-10-20 2017-10-09 Anti-proliferative agents for treating pah

Publications (1)

Publication Number Publication Date
MX2019004602A true MX2019004602A (es) 2019-06-17

Family

ID=60138667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004602A MX2019004602A (es) 2016-10-20 2017-10-09 Agentes anti-proliferativos para tratar pah.

Country Status (15)

Country Link
US (2) US10849903B2 (es)
EP (2) EP3804724B1 (es)
JP (2) JP2018076290A (es)
KR (1) KR20190071763A (es)
CN (1) CN109843297A (es)
AU (1) AU2017345367A1 (es)
BR (1) BR112019005526A2 (es)
CA (1) CA3040815C (es)
ES (2) ES2934846T3 (es)
IL (1) IL266026A (es)
MX (1) MX2019004602A (es)
RU (1) RU2019111887A (es)
SG (1) SG11201902523UA (es)
TW (1) TWI656876B (es)
WO (1) WO2018073687A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220003565A (ko) 2019-04-19 2022-01-10 화이자 인코포레이티드 Pah를 치료하기 위한 항증식제
TWI769382B (zh) * 2019-06-21 2022-07-01 長庚大學 利博西林用於製備治療罹患磷酸二酯酶４介導疾病的患者的醫藥組合物及用途
CN112569357B (zh) * 2019-09-30 2023-03-28 深圳奥萨制药有限公司 双重内皮素受体拮抗剂与利尿剂的组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
JP2003531899A (ja) 2000-05-03 2003-10-28 エルジー ライフ サイエンス リミテッド ３−ヒドロキシクロメン−４−オン構造を有するｃｄｋ阻害剤
WO2003062236A1 (en) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
MXPA06000484A (es) 2003-07-11 2006-04-05 Warner Lambert Co Sal de isetionato de un inhibidor selectivo de la quinasa 4 dependiente de ciclina.
WO2006074985A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
RU2009108006A (ru) 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов
US20090325997A1 (en) * 2006-11-23 2009-12-31 Ergonex Pharma Gmbh Pharmaceutical Compositions For The Treatment Of Capillary Arteriopathy
JP5681855B2 (ja) * 2007-10-12 2015-03-11 アストラゼネカ エービー プロテインキナーゼの阻害剤
WO2009121031A1 (en) * 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
WO2010000913A1 (en) 2008-07-04 2010-01-07 Lauri Ilmari Pekansaari Sauna oven center boiler
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
AU2010291199A1 (en) 2009-09-04 2012-03-08 Novartis Ag Pyrazinylpyridines useful for the treatment of proliferative diseases
MX2012002761A (es) 2009-09-04 2012-04-19 Novartis Ag Bipiridinas utiles para el tratamiento de enfermedades proliferativas.
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CN106967074A (zh) 2010-10-25 2017-07-21 G1治疗公司 Cdk抑制剂
CA2818229A1 (en) 2010-11-19 2012-05-24 Piramal Enterprises Limited Pharmaceutical combination of paclitaxel and a cdk inhibitor
SG11201505680RA (en) * 2013-02-21 2015-09-29 Pfizer Solid forms of a selective cdk4/6 inhibitor
TN2016000435A1 (en) * 2014-04-11 2018-04-04 Bayer Pharma AG Novel macrocyclic compounds.
CN105294681B (zh) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
CN105294655B (zh) 2014-07-26 2019-03-15 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2016053040A1 (ko) 2014-10-02 2016-04-07 주식회사 엘지화학 리튬 이차 전지용 전해액 첨가제, 상기 전해액 첨가제를 포함하는 비수성 전해액 및 리튬 이차 전지
CN104758292B (zh) * 2015-03-06 2018-05-01 天津医科大学总医院 Pd-0332991在制备防治耐药肿瘤药物的用途
US10822337B2 (en) * 2015-04-01 2020-11-03 Rigel Pharmaceuticals, Inc. TGF-β inhibitorC

Also Published As

Publication number Publication date
RU2019111887A (ru) 2020-11-20
RU2019111887A3 (es) 2020-11-20
CA3040815A1 (en) 2018-04-26
AU2017345367A1 (en) 2019-04-04
US10849903B2 (en) 2020-12-01
EP3528812A1 (en) 2019-08-28
TW201827054A (zh) 2018-08-01
SG11201902523UA (en) 2019-05-30
EP3528812B1 (en) 2020-12-30
US20190240226A1 (en) 2019-08-08
JP2021038265A (ja) 2021-03-11
EP3804724A1 (en) 2021-04-14
IL266026A (en) 2019-06-30
WO2018073687A1 (en) 2018-04-26
KR20190071763A (ko) 2019-06-24
CA3040815C (en) 2021-07-20
US20210186974A1 (en) 2021-06-24
ES2934846T3 (es) 2023-02-27
TWI656876B (zh) 2019-04-21
JP2018076290A (ja) 2018-05-17
BR112019005526A2 (pt) 2019-06-18
CN109843297A (zh) 2019-06-04
ES2852349T3 (es) 2021-09-13
US11439646B2 (en) 2022-09-13
EP3804724B1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
SA519401541B1 (ar) [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات
PH12019500776A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
EP4353747A3 (en) Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
MX2024010140A (es) Nuevos metodos.
PH12018502134A1 (en) Methods of treating pediatric cancers
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX2022000709A (es) Regimenes de tratamiento con dexmedetomidina no sedante.
MX2021002322A (es) Nuevos metodos.
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2019004602A (es) Agentes anti-proliferativos para tratar pah.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
JOP20220042A1 (ar) طرق لعلاج فرط فينيل ألانين الدم
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
MX2017001461A (es) Terapia de combinacion.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
NZ757557A (en) Methods of preventing or treating ophthalmic diseases
EA201992414A1 (ru) Комбинация nk1-антагониста и способ лечения синуклеинопатий